



Application Form for Initial Review

Maharshi Devraha Baba Autonomous State Medical College, Deoria UP

EC Ref.No. EC/NEW/INST/2024/4277

General Instructions: a) Tick one or more as applicable. Mark NA if not applicable
b) Attach additional sheets if required
c) May select more than one option

SECTION A - BASIC INFORMATION

1. ADMINISTRATIVE DETAILS

(a) Name of Organization:

(b) Name of Ethics Committee:

(c) Name of Principal Investigator:

(d) Department/Division: (e) Date of submission:

(f) Type of review requested¹:

Exemption from review ☐

Expedited review ☐

Full committee review ☐

(g) Title of the study:

.....
.....

(i) Details of Investigators:

Name	Designation and Qualification	Department and Institution	Address for communication ²
Principal Investigator/Guide			
Co-investigator/student/fellow			

(k) Duration of the study:

¹ Refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017 on Page 36 Table 4.2. for types of review

² Include telephone/mobile, fax numbers and email id

2. FUNDINGDETAILSANDBUDGET

(a) Totalestimatedbudgetforsite:.....

(b) Self-funding ☐ Institutional funding ☐ Fundingagency(*Specify*) ☐

.....

SECTIONB-RESEARCHRELATEDINFORMATION

3. OVERVIEWOFRESEARCH

(a) Laysummary³(within300words):.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

(b) Typeofstudy:

BasicSciences ☐	Clinical ☐	CrossSectional ☐
Retrospective ☐	Epidemiological/ ☐	CaseControl ☐
Prospective ☐	PublicHealth ☐	Cohort ☐
Qualitative ☐	Socio-behavioral ☐	SystematicReview ☐
Quantitative ☐	Biologicalsamples ☐	
MixedMethod ☐	Anyothers(<i>Specify</i>) ☐	

.....

4. METHODOLOGY

(a) Samplesize/numberofparticipants(*asapplicable*)

Atsite.....At other sites (If applicable)

Control g r o u p Study group

Justification for the sample size chosen (100 words); In case of qualitative study, mention the criteria used
forsaturation

.....

.....

.....

.....

.....

³Summarizeinthesimplestpossiblewaysuchthatapersonwithnopriorknowledgeofthesubjectcaneasilyunderstandit.

(b) Isthereanexternal laboratory/outsourcinginvolvedforinvestigations?⁴

Yes ☐ No ☐ NA ☐

(c) Has the proposal been reviewed for thescientificquality?

Yes ☐ No ☐

If Yes then,

Dateofreview:

dd	mm	yy
----	----	----

Comments of Research AdvisoryCommittee,if any (100words)

.....

.....

.....

.....

SECTIONC:PARTICIPANTRELATEDINFORMATION

5. RECRUITMENTANDRESEARCHPARTICIPANTS

(a) Typeofparticipantsinthestudy:

Healthyvolunteer ☐

Patient ☐

Vulnerablepersons/Specialgroups ☐

Others ☐

(Specify)

Whowilldotherecruitment?

Participant recruitment methods used:

Posters/
leaflets/Letters ☐

TV/Radio ads/ ☐

Patients/Family/Friends ☐
visitinghospitals

Telephone ☐

Social
media/Institutionwe
bsite ☐

Others ☐

(Specify)

(b) i. Will there be vulnerable persons /special groups involved?

Yes ☐ No ☐ NA ☐

ii. Ifyes,typeofvulnerablepersons/specialgroups

Childrenunder18yrs ☐

Pregnantorlactatingwomen ☐

☐Differentlyabled(Mental/Physical)

☐ Employees/Students/Nurses/Staff ☐ Elderly

☐ Institutionalized

☐ Economicallyandsociallydisadvantaged ☐

Refugees/Migrants/Homeless

☐ Terminallyill(stigmatizedorrarediseases) ☐

Anyother(Specify):

☐

iii. Providejustificationforinclusion/exclusion.....

.....

.....

iv.

Arethereanyadditionalsafeguardstoprotectresearchparticipants?

.....

.....

(c) Is there any reimbursement to the participants? Yes ☐ No ☐

If yes, Monetary ☐ Non-monetary ☐ Provided details

.....
.....

(d) Are there any incentives to the participants? Yes ☐ No ☐

If yes, Monetary ☐ Non-monetary ☐ Provided details

.....
.....

(e) Are there any participant recruitment fees/incentives for the study provided to the PI/Institution?

If yes, Monetary ☐ Non-monetary ☐ Provided details Yes ☐ No ☐

.....
.....

6. BENEFITS AND RISKS

(a) i. Are there any anticipated physical/social/psychological discomforts/risk to participants? Yes ☐ No ☐

If yes, categorize the level of risk⁵:

Less than Minimal risk ☐ Minimal risk ☐

Minor increase over minimal risk or low risk ☐ More than minimal risk or high risk ☐

ii. Describe the risk management strategy:

.....
.....

(b) What are the potential benefits from the study? For

	Yes	No	If yes,	Direct	Indirect
the participant	☐	☐		☐	☐
For the	☐	☐		☐	☐
society/community	☐	☐		☐	☐
For improvement in science					

Please describe how the benefits justify the risks

.....
.....

(c) Are adverse events expected in the study⁶? Yes ☐ No ☐ NA

☐ Are reporting procedures and management strategies described in the study? Yes ☐ No ☐ If

Yes, Specify

.....
.....

7. INFORMED CONSENT

(a) Version number and date of Participant Information Sheet (PIS):

Version number and date of Informed Consent Form (ICF):

⁵For categories of risk refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 6 Table 2.1

⁶The term adverse events in this regard encompass both serious and non-serious adverse events.

(b) Type of consent planned for:

Signed consent	☐	Verbal/Oral consent	☐	Waiver of consent	☐	Witnessed consent	☐
Consent from LAR (If so, specify from whom)	☐	For children < 7 yrs parental/LAR consent	☐	Verbal assent from minor (7-12 yrs) along with parental consent	☐	Written assent from minor (13-18 yrs) along with parental consent	☐
Audio-Video (AV) consent	☐	Other (specify)	☐				

(c) Who will obtain the informed consent?

PI/Co-PI ☐ Nurse/Counselor ☐ Research Staff ☐ Other ☐ (Specify)

Any tools to be used

(d) Participant Information Sheet (PIS) and Informed Consent Form (ICF)

English ☐ Local language ☐ Other ☐ (Specify)

List the languages in which translations were done

If translation has not been done, please justify

.....

(e) Are you seeking waiver of consent? If yes, what are the reasons.

Yes ☐ No ☐

.....

.....

(f) Provide details of consent requirements for previously stored samples if used in the study⁷

.....

.....

(g) Elements contained in the Participant Information Sheet (PIS) and Informed Consent Form (ICF)

Simple language	☐	Data/Samples sharing	☐	Compensation for study related injury	☐
Risks and discomforts	☐	Need to recontact	☐	Statement that consent is voluntary	☐
Alternatives to participation	☐	Confidentiality	☐	Commercialization/Benefit sharing	☐
☐ Right to withdraw	☐	Storage of samples	☐	Statement that study involves research	☐
Benefits	☐	Return of research	☐	Use of photographs/Identifying data	☐
Purpose and procedure	☐	results ☐ Payment for participation	☐	Sponsor contact information	☐
Others (Specify)	☐	ion ☐			

.....

8. PAYMENT/COMPENSATION

(a) Who will bear the costs related to participation and procedures⁸?

PI ☐ Institution ☐ Sponsor ☐ Other agencies ☐ (specify)

(b) Is there a provision for free treatment of research related injuries?

Yes ☐ No ☐

If yes, then who will provide the treatment?

(c) Is there a provision for compensation of research related SAE?

If yes, specify.

Yes ☐ No ☐

Sponsor ☐ Institutional/Corpus fund ☐ Project grant ☐ Insurance ☐

(d) Is there any provision for medical treatment or management till the relatedness is determined for injury to the participants during the study period? If yes, specify.

Yes ☐ No ☐

⁷Information on non-consent requirements can be found at National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 54 in Section 5.8.

⁸Enclose undertaking from PI confirming the same

9. STORAGE AND CONFIDENTIALITY

(a) Identifying Information: Study involves samples/data (*specify*):

Anonymous/Unidentified ☐ Anonymized: Reversibly coded ☐ Irreversibly coded ☐ Identifiable ☐ If identifiers must be retained, what additional precautions will be taken to ensure that access is limited /data is safeguarded? (e.g. data stored in a cabinet, password protected computer etc.).....

.....

.....

.....

.....

(b) Who will be maintaining the data pertaining to the study? (c) When will the data be analyzed⁹ and by whom?

(d) For how long will the data be stored?

(e) Do you propose to use stored samples/data in future studies? Yes ☐ No ☐ Maybe ☐

If yes, explain how you might use stored material/data in the future?

.....

.....

.....

SECTION D: OTHER ISSUES

10. PUBLICATION, BENEFIT SHARING AND IPR ISSUES

(a) Will the results of the study be reported and disseminated? If yes, specify. Yes ☐ No ☐

.....

.....

(b) Will you inform participants about the results of the study? Yes ☐ No ☐

(c) Are there any arrangements for continued provision of the intervention for participants, if effective, once the study has finished? If yes, describe in brief (Max 50 words) Yes ☐ No ☐ NA ☐

.....

.....

(d) Is there any plan for post-research benefit sharing with participants? If yes, specify Yes ☐ No ☐

.....

.....

(e) Is there any commercial value or a plan to patent/IPR issues? If yes, please provide details Yes ☐ No ☐

.....

.....

(f) Do you have any additional information to add in support of the application, which is not included elsewhere in the form? If yes, provide details. Yes ☐ No ☐

.....

.....

.....

.....

⁹ For example, a data entry room, a protected computer etc.

SECTION:DECLARATIONANDCHECKLIST¹⁰

11.DECLARATION(Pleasetickasapplicable)	
☐	I/We certify that the information provided in this application is complete and correct.
☐	I/We confirm that all investigators have approved the submitted version of proposal/related documents.
☐	I/We confirm that this study will be conducted in accordance with the latest ICMR National Ethical Guidelines for Biomedical and Health Research involving Human Participants and other applicable regulations and guidelines.
☐	I/We confirm that this study will be conducted in accordance with the Drugs and Cosmetics Act 1940 and its Rules 1945 as amended from time to time, GCP guidelines and other applicable regulations and guidelines.
☐	I/We will comply with all policies and guidelines of the institute and affiliated/collaborating institutions where this study will be conducted.
☐	I/We will ensure that personnel performing this study are qualified, appropriately trained and will adhere to the provisions of the EC approved protocol.
☐	I/We declare that the expenditure in case of injury related to the study will be taken care of.
☐	I/We confirm that an undertaking of what will be done with the leftover samples is provided, if applicable.
☐	I/We confirm that we shall submit any protocol amendments, adverse events report, significant deviations from protocols, progress reports (if required) and a final report and also participate in any audit of the study if needed.
☐	I/We confirm that we will maintain accurate and complete records of all aspects of the study.
☐	I/We will protect the privacy of participants and assure confidentiality of data and biological samples.
☐	I/We hereby declare that I/any of the investigators, researchers and/or closer relative(s), have no conflict of interest (Financial/Non-Financial) with the sponsor(s) and outcome of study.
☐	I/We have the following conflict of interest (PI/Co-PI): 1..... 2.....

Name of PI:

Signature:..... dd mm yy

Name of Co-PI:.....

Signature:..... dd mm yy

Name of Co-PI:.....

Signature:..... dd mm yy

¹⁰ These formats are adaptable and can be modified by the Ethics Committee members depending on their needs and requirements. Acknowledgement for Receipt of Application (Copy to be provided to PI)

12.CHECKLIST

S.No	Items	Yes	No	NA	Enclosure No	EC Remarks (If applicable)
ADMINISTRATIVE REQUIREMENTS						
1	Cover letter	☐	☐	☐		
2	Brief CV of all Investigators	☐	☐	☐		
3	Good Clinical Practice (GCP) training of investigators in last 3 years	☐	☐	☐		
4	Approval of scientific committee	☐	☐	☐		
5	EC clearance of other centers*	☐	☐	☐		
6	Agreement between collaborating partners*	☐	☐	☐		
7	MTA between collaborating partners*	☐	☐	☐		
8	Insurance policy/certificate	☐	☐	☐		
9	Evidence of external laboratory credentials in case of an externally outsourced laboratory study QA/QC certification	☐	☐	☐		
10	Copy of contractor agreements signed with the sponsor or donor agency	☐	☐	☐		
11	Provide all significant previous decisions (e.g. those leading to a negative decision or modified protocol) by other ECs/Regulatory authorities for proposed study (whether in same location or elsewhere) and modification(s) to protocol	☐	☐	☐		
PROPOSAL RELATED						
12	Copy of the detailed protocol ¹¹	☐	☐	☐		
13	Investigators Brochure (If applicable for drug/biologicals/device trials)	☐	☐	☐		
14	Participant Information Sheet (PIS) and Participant Informed Consent Form (ICF) (English and translated)	☐	☐	☐		
15	Assent form for minors (12-18 years) (English and Translated)	☐	☐	☐		
16	Proforma/Questionnaire/Case Report Forms (CRF)/Interview guides/Guides for Focused Group Discussions (FGDs) (English and translated)	☐	☐	☐		
17	Advertisement/material to recruit participants (fliers, posters etc)	☐	☐	☐		
PERMISSION FROM GOVERNING AUTHORITIES						
	Other permissions	Required	Not required	Received	Applied dd/mm/yy	EC Remarks
18	CTRI	☐	☐	☐		
19	DCGI	☐	☐	☐		
20	HMSC	☐	☐	☐		
21	NAC-SCRT	☐	☐	☐		
22	ICSCR	☐	☐	☐		
23	RCGM	☐	☐	☐		
24	GEAC	☐	☐	☐		
25	BARC	☐	☐	☐		
26	Tribal Board	☐	☐	☐		
27	Others (Specify)	☐	☐	☐		
ANY OTHER RELEVANT INFORMATION/DOCUMENTS RELATED TO THE STUDY						
	Item	YES	NO	NA	Enclosure no.	EC Remarks
28						
29						

*Form multicentric research.

MTA - Material Transfer Agreement; CTRI - Clinical Trial Registry - India; DCGI - Drug Controller General of India; HMSC - Health Ministry's Screening Committee; NAC-SCRT - National Apex Committee for Stem Cell Research and Therapy; IC-SCR - Institutional committee for Stem Cell Research; RCGM - Review Committee on Genetic Manipulation; GEAC - Genetic Engineering Approval Committee; BARC - Bhabha Atomic Research Centre
¹¹ Refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, section 4 Page no. 35 Box 4.4(b)

Version 1

